‘It’s a very individual disease’, Alzheimer’s activist urges policymakers to boost understanding
A diagnosis of Alzheimer’s disease (AD) can be devastating, both for the individual and their family. While AD impacts each person differently, one thing that all patients can benefit from is having more time to understand what changes lie ahead, and plan for their future. At Lilly, we recognize that access to early and accurate diagnosis is essential to connecting patients and their families to the care and support they need.
Greater understanding of the underlying mechanisms of AD, combined with new diagnostic innovations, means we are now able to identify AD much earlier in the disease continuum. Unfortunately, access to these diagnostic breakthroughs varies significantly across Europe. In this article, the third from an independent series supported by Lilly, AD activist Jan Runar Eliassen talks about his own diagnostic journey – as well as issuing a rallying cry to policymakers to better recognize the highly individualized needs of people with AD and consider the importance of early diagnosis in their decision making.
EU-CAR 2024-156
Tags in this Article:
No categories
Related articles
BE PIONEERING: The benefits of unlocking the value of diagnostic innovation in...
There is an urgent need to improve access to new innovations in the diagnosis and treatment of Alzheimer's disease. Embracing breakthroughs such as blood-based biomarker testing, has the potential to transform timely, accurate diagnosis for the benefit of patients and healthcare systems.
Rewriting Alzheimer’s future together – a call to action for G7 countries
While treatments for Alzheimer’s disease have advanced dramatically, greater political will is needed to harness their potential and bring innovation to the fore. Leaders have a crucial opportunity to collaborate, change the current discourse around Alzheimer’s disease and usher in a new era – one of support, understanding and hope.
“Rethinking AD Pathway: From Diagnosis to Care”
There is an urgent need to improve access to new innovations in the diagnosis and treatment of Alzheimer's disease. Embracing breakthroughs such as blood-based biomarker testing, has the potential to transform timely, accurate diagnosis for the benefit of patients and healthcare systems